Valeant has drawn scrutiny from Congress, hospitals and patients for sharply increasing their prices, the NYT reports.» Read More
Shares of Valeant Pharmaceuticals plunged after the drug maker was subpoenaed over pricing. CNBC's Meg Tirrell covers what it means for big pharma.
One of the most valuable Silicon Valley startups is under fire, according to the Wall Street Journal.
U.S. prosecutors are probing Valeant Pharmaceuticals over how it prices and distributes drugs, the Canadian pharma giant revealed late Wednesday.
CNBC's Meg Tirrell reports that Turing Pharmaceuticals CEO Martin Shkreli has not kept his promise to lower the price of Daraprim.
Voter initiatives in California and Ohio to control prescription med prices have ramifications for the presidential contest.
The same drug development news that's hurting Eli Lilly shares might be good for Amgen and Sanofi-Regeneron.
Tony Butler, Managing Director and Analyst, Guggenheim Securities, looks at the biotech space and whether there are any bargains to be found.
CNBC's Meg Tirrell reports that Eli Lilly's decision to stop development of a heart drug has caused shares to take a big hit today.
Stock markets are fixated on Fed policy, but two experts believe investors should forget the U.S. central bank for now.
James West, senior healthcare analyst for Results Healthcare, talks about biotech stocks and explains the differences biotech and pharmaceutical companies.
Talking biotech, with CNBC's Meg Tirrell and the "Godfather of biotech," Biogen Chairman Stelios Papadopoulos.
Drugmaker Roche said its experimental medicine for multiple sclerosis performed better in a late-stage clinical trial than a commonly used therapy.
Feeling pretty good about these stocks
CNBC's Bertha Coombs tracks the Nasdaq as the index briefly followed the Dow and S&P 500 in recovering September's losses with a biotech boost.
Express Scripts, the largest pharmacy benefits manager in the U.S., says it's got a plan to fight drug price increases: Refuse to pay.
The nation's largest pharmacy benefit manager plans to control costs from new cholesterol drugs through discounts and restricting use.
Axovant Sciences CEO Vivek Ramaswamy discusses how his company could lead the way to a treatment for Alzheimers.
CNBC's Bertha Coombs reports on what is dragging down the biotech sector.
Another big selloff in biotech, as the IBB is down more than 5 percent today. Are there still opportunities in the sector or is it just too risky right now? With Duncan Rolph, Miracle Mile Advisors.
CNBC's Bertha Coombs reports on biotech's 6 percent drop on the day.
Get the best of CNBC in your inbox